US9155697B2 - Stable liquid compositions for treating stomatitis comprising epidermal growth factor - Google Patents

Stable liquid compositions for treating stomatitis comprising epidermal growth factor Download PDF

Info

Publication number
US9155697B2
US9155697B2 US12/444,961 US44496107A US9155697B2 US 9155697 B2 US9155697 B2 US 9155697B2 US 44496107 A US44496107 A US 44496107A US 9155697 B2 US9155697 B2 US 9155697B2
Authority
US
United States
Prior art keywords
growth factor
liquid composition
epidermal growth
pharmaceutical composition
liquid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US12/444,961
Other versions
US20100035809A1 (en
Inventor
Sun-Hee Kim
Sang-Kil Lee
Chae-Ha Yoon
Sun-Mee Yang
Sang-Hyun Nam
Kyeong-Sun Shin
Seung-Kook Park
Sang-Wook Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Co Ltd
Original Assignee
Daewoong Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Co Ltd filed Critical Daewoong Co Ltd
Assigned to DAEWOONG CO., LTD. reassignment DAEWOONG CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIM, SUN-HEE, LEE, SANG-KIL, NAM, SANG-HYUN, PARK, SEUNG-KOOK, SHIN, KYEONG-SUN, YANG, SUN-MEE, YOON, CHAE-HA, LEE, SANG-WOOK
Publication of US20100035809A1 publication Critical patent/US20100035809A1/en
Application granted granted Critical
Publication of US9155697B2 publication Critical patent/US9155697B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1808Epidermal growth factor [EGF] urogastrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF] (urogastrone)

Definitions

  • Stomatitis is a disease that affects oral mucosa. Specifically, stomatitis is an inflammation which is caused or exacerbated by pharmaceutical treatment, specifically by a chemotherapeutic or radioactive treatment, and in some cases, is accompanied by an ulcer(s). Stomatitis exhibits mild to severe symptoms. Patients suffering from severe stomatitis cannot eat food through their mouth. Meanwhile, erythematous mucositis, which is a type of stomatitis, appears within three days, more commonly within 5-7 days after exposure to a chemotherapeutic or radioactive treatment.
  • Erythematous mucositis can progress to an ulcerative mucositis within 7 days after exposure to a chemotherapeutic treatment in general and some erythematous mucositises can progress to such a serious level that any drug treatment should be stopped.
  • US Patent Application Pub. No. 2002/0219634 discloses a bioadhesvie solution or suspension having a viscosity ranging from 50-50,000 cps
  • Korean Patent Application Pub. No. 2005-55858 discloses a drug delivery system for oral cavity in the form of a liquid or gel drug including a mixture of a hydrophilic polymer and a water-insoluble polymer.
  • the epidermal growth factor and the adhesive polymer can be prepared in a liquid type and then formulated in a spray form.
  • the liquid formulation method decreases stability of the epidermal growth factor due to use of an aqueous medium in which molecules move relatively more actively.
  • a liquid composition for treating stomatitis including an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and dextran.
  • EDTA ethylenediaminetetraacetic acid
  • a spray for treating stomatitis including the liquid composition.
  • the liquid composition according to the present invention includes a stabilizer selected from EDTA and salts thereof and a certain amino acid and inorganic acid salts thereof, and thus, physicochemical and biological stabilities of an epidermal growth factor can be significantly improved. Therefore, the liquid composition can be stored or distributed for a long period of time.
  • the liquid composition includes an adhesive polymer and thus, when the liquid composition is ejected in a spray form into the mouth of a user, the liquid composition can be quickly attached to an inflammation site and can exhibit a pharmaceutical effect for a long period of time.
  • the liquid composition according to the present invention includes the adhesive polymer and thus the liquid composition can be quickly attached to the inflammation site when applied into the oral cavity, and a sufficient viscosity can be maintained constant.
  • the adhesive polymer can be celluloses, such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, or sodium carboxymethyl cellulose; a hydrophilic polymer, such as sodium hyaluronate, carbomer (for example, Carbopol 940TM (ISP, USA)), xanthan gum, gellan gum, pullulan, pectin, or starches (for example, corn starch); a non-ionic surfactant, such as a copolymer of polyoxyethylene and polyoxypropylene; or a combination of these.
  • the reconstitution spray refers to a type of administrating a mixture of a solvent unit (that is, an adhesive excipient solution) and a primary component unit (that is, a liquid mixture composition of a human growth hormone and a stabilizer), in which when not used, the solvent unit is separated from the primary component unit.
  • a solvent unit that is, an adhesive excipient solution
  • a primary component unit that is, a liquid mixture composition of a human growth hormone and a stabilizer
  • the spray used in the present invention can be a reconstitution spray which includes a solvent unit including an adhesive polymer and a primary component unit including an epidermal growth factor and a stabilizer, in which the solvent unit and the primary component unit are contained in different vessels from each other.
  • a stabilizer (EDTA disodium salt, L-histidine, hydrochloric acid L-arginin, L-lysine hydrochloride, or dextran 70) and an epidermal growth factor were dissolved in the homogeneous mixture and water was added thereto until the final volume of the liquid composition reached 1 L.
  • a liquid composition was prepared in the same manner as the method described above, except that no stabilizer was added.
  • Example 1 Feeling of 7.5 10.0 9.5 9.5 9.0 10.0 7.0 Use Feeling of 7.0 9.0 9.5 8.0 9.0 8.5 2.0 Wearing Others bitter and None None None A bit None bitter and acrid tastes bitter Taste acrid Tastes Feeling of Use: from 10 (excellent, no stimulus) to 1 (bad, stimulus and painful) Feeling of Wearing: from 10 (most of the drug used remains in the lesion) to 1 (most of the drug used flows to the esophagus)

Abstract

Provided is a liquid composition for treating stomatitis, the liquid composition including: an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and dextran. The liquid composition includes a stabilizer selected from EDTA (or salts thereof) and a certain amino acid (or inorganic acid salts thereof) and thus, physicochemical and biological stability of the epidermal growth factor can be substantially increased. Thus, the liquid composition can be stored and distributed for a long period of time. The stabilized composition includes an adhesive polymer, and thus, when ejected in a spray form in the mouth of a user, the liquid composition can be quickly attached to an inflammation site and exhibits effectiveness for a long period of time.

Description

TECHNICAL FIELD
The present invention relates to stable liquid compositions for treating stomatitis including an epidermal growth factor.
BACKGROUND ART
Stomatitis is a disease that affects oral mucosa. Specifically, stomatitis is an inflammation which is caused or exacerbated by pharmaceutical treatment, specifically by a chemotherapeutic or radioactive treatment, and in some cases, is accompanied by an ulcer(s). Stomatitis exhibits mild to severe symptoms. Patients suffering from severe stomatitis cannot eat food through their mouth. Meanwhile, erythematous mucositis, which is a type of stomatitis, appears within three days, more commonly within 5-7 days after exposure to a chemotherapeutic or radioactive treatment. Erythematous mucositis can progress to an ulcerative mucositis within 7 days after exposure to a chemotherapeutic treatment in general and some erythematous mucositises can progress to such a serious level that any drug treatment should be stopped.
Among patients who are treated with chemotherapy, a large number of patients suffer from mucositis although the severity thereof may differ. So, there is a great need to develop an effective and simple method for treating stomatitis. Conventionally, stomatitis is treated by oral cleansing or administration with various kinds of vitamins. Specifically, stomatitis caused by a chemotherapeutic or radioactive treatment can be treated by mouth wash administration of allopurinol or sodium alginate (Archives, Vol. 55, No. 1:28, 1995; Japanese Journal of Hospital Pharmacy, Vol. 18, No. 5:510, 1992; Japanese Journal of Nursing Acts, Vol. 37, No. 15:44, 1991; The Journal of Japanese Society for Cancer Therapy, Vol. 25, No. 6:1129, 1990). However, such a mouth wash administration shows low effectiveness in alleviating symptoms, is ineffective for serious stomatitis, and requires a long administration period to obtain any improvement in symptoms. Due to these problems, there have been many efforts to develop a drug or method for treating stomatitis which shows a high curative effect in a short period of time.
Most conventional compositions for treating stomatitis are prepared in ointments or patches which contain an adhesive polymer. For example, U.S. Pat. No. 56,578,310 discloses a bioadhesive ointment formed of an emulsion containing mineral oil, hydroxyl propyl methyl cellulose, and the like; and Korean Patent Application Pub. No. 1994-0023469 discloses plasters having a double film structure containing a steroid drug and a method of preparing the same.
As for other forms excluding ointments or patches, US Patent Application Pub. No. 2002/0219634 discloses a bioadhesvie solution or suspension having a viscosity ranging from 50-50,000 cps, and Korean Patent Application Pub. No. 2005-55858 discloses a drug delivery system for oral cavity in the form of a liquid or gel drug including a mixture of a hydrophilic polymer and a water-insoluble polymer.
Meanwhile, International Publication No. WO 03/95637 discloses use of an epidermal growth factor for treating stomatitis. The epidermal growth factor which is known as urogastrones is a polypeptide having a molecular weight of 6045 with 53 amino acids and three disulfide bonds. The epidermal growth factor stimulates mitosis and cell growth of various kinds of cells, such as an epithelial cell or a mesenchymal cell, and hinders gastric acid secretory, and thus, the epidermal growth factor is effective in treating a gastric ulcer or a wound on skin or a cornea (Carpenter, Experimental Cell Research, 164:1-10, 1986). Accordingly, if the epidermal growth factor is formulated together with an adhesive polymer, such as hydroxypropyl methyl cellulose, high effectiveness in treating stomatitis can be obtained.
This method, however, is inconvenient and can cause a second infection because ointments or patches which contain the epidermal growth factor and the adhesive polymer should be directly applied or attached to an oral inflammation or a wound by a patient. To avoid these problems, the epidermal growth factor and the adhesive polymer can be prepared in a liquid type and then formulated in a spray form. The liquid formulation method, however, decreases stability of the epidermal growth factor due to use of an aqueous medium in which molecules move relatively more actively.
DETAILED DESCRIPTION OF THE INVENTION Technical Problem
Inventors of the present application found that a liquid formulation having high stability can be prepared using a stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), which is a conventional antioxidant, salts thereof, dextran, and certain amino acids.
The present invention provides a stable liquid composition for treating stomatitis including: a stabilizer selected from EDTA and salts thereof, dextran, and certain amino acids; an epidermal growth factor; and an adhesive polymer.
The present invention also provides a spray for treating stomatitis including the liquid composition.
Technical Solution
According to an aspect of the present invention, there is provided a liquid composition for treating stomatitis: including an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and dextran.
According to another aspect of the present invention, there is provided a spray for treating stomatitis including the liquid composition.
The present invention will be described in detail.
In the present specification, the term ‘stomatitis’ is an inflammation which affects oral mucosa, can be caused or exacerbated by a pharmaceutical treatment, specifically by a chemotherapeutic or radioactive treatment, and can be accompanied by an ulcer. Stomatitis may exhibit from mild to such severe symptoms that patients suffering from stomatitis cannot eat food through their mouth.
The liquid composition according to the present invention includes a stabilizer selected from EDTA and salts thereof and a certain amino acid and inorganic acid salts thereof, and thus, physicochemical and biological stabilities of an epidermal growth factor can be significantly improved. Therefore, the liquid composition can be stored or distributed for a long period of time. The liquid composition includes an adhesive polymer and thus, when the liquid composition is ejected in a spray form into the mouth of a user, the liquid composition can be quickly attached to an inflammation site and can exhibit a pharmaceutical effect for a long period of time.
The liquid composition according to the present invention includes an epidermal growth factor acting as an active component. The epidermal growth factor can be a natural or recombinant protein in an amount which is therapeutically effective. That is, when the liquid composition is formulated in a unit form, for example, in a spray form, the amount of the epidermal growth factor may be in the range from about 0.1 to 1,000 μg/mL, preferably from 0.5 to 500 μg/mL, and more preferably 1.0 to 100 μg/mL. A liquid composition prepared to be formulated into a specific dosage form may include the epidermal growth factor in an amount ranging from 0.0001 to 0.01 w/v % based on the total amount of the liquid composition.
The liquid composition according to the present invention includes at least one stabilizer selected from the group consisting of: EDTA and salts thereof, such as disodium salt, calcium diodium salt, or trisodium salt; histidine; lysine and inorganic acid salts thereof, such as hydrochloride salt of lysine; arginin and inorganic acid salts thereof, such as a hydrochloride salt of arginin; and dextran. The sterilizer can be EDTA disodium salt, L-histidine, L-lysine hydrochlorate salt, L-arginin hydrochloride salt, and/or dextran having an average molecular weight ranging from 40,000 to 100,000 Da. Preferably, the stabilizer can include at least one selected from the group consisting of histidine, lysine, and arginin. For example, the stabilizer can include EDTA disodium salt and/or L-histidine.
The amount of the stabilizer present in the liquid composition may differ according to the kind of the stabilizer used. For example, the amount of the stabilizer may be in the range from 0.01 to 10 w/v %, specifically 0.05 to 5 w/v %, based on the total amount of the liquid composition. When the amount of the stabilizer is less than 0.01 w/v %, stabilization of the epidermal growth factor may not be achieved. On the other hand, when the amount of the stabilizer is greater than 10 w/v %, stability of the epidermal growth factor may be rather decreased.
The liquid composition according to the present invention includes the adhesive polymer and thus the liquid composition can be quickly attached to the inflammation site when applied into the oral cavity, and a sufficient viscosity can be maintained constant. The adhesive polymer can be celluloses, such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, or sodium carboxymethyl cellulose; a hydrophilic polymer, such as sodium hyaluronate, carbomer (for example, Carbopol 940™ (ISP, USA)), xanthan gum, gellan gum, pullulan, pectin, or starches (for example, corn starch); a non-ionic surfactant, such as a copolymer of polyoxyethylene and polyoxypropylene; or a combination of these. The adhesive polymer can be a copolymer of polyoxyethylene and polyoxypropylene in a weight average molecular weight from 7,000 to 15,000, such as poloxamer 407™ (BASF, USA), or poloxamer 188™ (BASF, USA).
The amount of the adhesive polymer present in the liquid composition according to the present invention may differ according to the kind of the polymer used. The amount of the adhesive polymer may be in the range from 0.01 to 20 w/v %, specifically from 0.1 to 10 w/v %, based on the total amount of the liquid composition. When the amount of the adhesive polymer is less than 0.01 w/v %, the viscosity of the formulation is low and the adhesive effect is low. On the other hand, when the amount of the adhesive polymer is greater than 20 w/v %, the viscosity of the formulation is high and thus, it may be difficult to prepare or formulate the liquid composition into, for example, a spray form.
The viscosity of the liquid composition may be in the range from 50 to 10,000 cps, and specifically from 500 to 5,000 cps (mPas). When the viscosity of the liquid composition is less than 50 cps, the viscosity of the liquid composition may too low and thus, the liquid composition does not remain in a wound site and may directly flow to an esophagus. On the other hand, when the viscosity of the liquid composition is greater than 10,000 cps, the viscosity of the liquid composition may be too high, and thus, the liquid composition formulated into a spray form cannot be ejected.
The liquid composition according to the present invention may include a pharmaceutically acceptable carrier. For example, the liquid composition can include an aqueous medium, such as water, purified water, or water for injection. In some cases, the liquid composition may further include a pH controller, a preservative, a sweetening agent, or a flavouring agent. In consideration of stability of the epidermal growth factor included as an active component in the liquid composition according to the present invention, pH of the liquid composition may be in the range from 5 to 8, and specifically from 6 to 7. The pH controller which controls the pH of the liquid composition can be a buffer solution containing sodium phosphate monobasic, sodium phosphate bibasic, or sodium citrate. The preservative can be methylparaben, propylparaben, benzylalcohol, or sodium benzoate. The amounts of the pH controller, the preservative, the sweetening agent, and the flavouring agent may be appropriately controlled by one of ordinary skill in the art. For example, the amount of the preservative, such as methylparaben or propylparaben, may be in the range from 0.01 to 1.0 w/v % based on the total amount of the liquid composition, but is not limited thereto.
The liquid composition according to the present invention can be formulated in various kinds of forms suitable for oral cavity administration, specifically in a spray form. That is, the present invention provides a spray for treating stomatitis including the liquid composition. The spray can be of an aerosol form, a pump spray form, or a reconstitution spray form. The pumping spray from and the reconstitution spray form can prevent a decrease in stability of an active component caused by a propellant.
The pump spray form refers to a type of ejecting a drug solution, that is, a liquid composition according to the present invention, contained in a vessel to which a negative pressure is applied by pumping.
The reconstitution spray refers to a type of administrating a mixture of a solvent unit (that is, an adhesive excipient solution) and a primary component unit (that is, a liquid mixture composition of a human growth hormone and a stabilizer), in which when not used, the solvent unit is separated from the primary component unit. For example, according to an embodiment of the present invention, the spray used in the present invention can be a reconstitution spray which includes a solvent unit including an adhesive polymer and a primary component unit including an epidermal growth factor and a stabilizer, in which the solvent unit and the primary component unit are contained in different vessels from each other.
Advantageous Effects
A liquid composition according to the present invention includes a stabilizer selected from EDTA (or salts thereof), dextran, and certain amino acids (or inorganic acid salts thereof) and thus, physicochemical and biological stabilities of an epidermal growth factor can be substantially increased. Thus, the liquid composition can be stored and distributed for a long period of time. The stabilized composition includes an adhesive polymer, and thus, when ejected in a spray form in the mouth of a user, the liquid composition can be quickly attached to an inflammation site and exhibits effectiveness for a long period of time.
Best Mode
The present invention will be described in further detail with reference to the following examples. These examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Examples 1-5 and Comparative Example 1
Liquid compositions were prepared according to the components and amounts shown in Table 1. In Table 1, the amount of each component is represented by w/v %. A buffer (sodium phosphate monobasic) and sodium chloride were dissolved using refined water, and then a pH controller (phosphoric acid) was added thereto in an appropriate amount to adjust the pH to a range from 6 to 7. The resultant solution was heated to 80° C. in order to dissolve a preservative (methylparaben), and then the heated solution was mixed with an adhesive polymer poloxamer 407™ (BASF, USA). The mixture was stirred until a homogeneous mixture was obtained. A stabilizer (EDTA disodium salt, L-histidine, hydrochloric acid L-arginin, L-lysine hydrochloride, or dextran 70) and an epidermal growth factor were dissolved in the homogeneous mixture and water was added thereto until the final volume of the liquid composition reached 1 L. As Comparative Example, a liquid composition was prepared in the same manner as the method described above, except that no stabilizer was added.
TABLE 1
Example Example Example Example Example Comparative
1 2 3 4 5 Example 1
Active Epidermal 0.005 0.005 0.005 0.005 0.005 0.005
Component growth factor
Buffer Sodium 0.36 0.36 0.36 0.36 0.36 0.36
solution phosphate
monobasic
Isotonic Sodium chloride 0.87 0.87 0.87 0.87 0.87 0.87
agent
Preservative Methyl paraben 0.1 0.1 0.1 0.1 0.1 0.1
Adhesive Poloxamer 407 6 6 6 6 6 6
polymer
(thickener)
Stabilizer EDTA disodium 0.5
salt
L-histidine 1
L-arginin 1
hydrochloride
L-lysine 1
hydrochloride
Dextran 70 0.1
Aqueous Refined water Appropriate Appropriate Appropriate Appropriate Appropriate Appropriate
medium amount amount amount amount amount amount
Viscosity (cps) 500-700
Test Example 1 Stability Test Against Thermal Stress
The liquid compositions prepared according to Examples 1-5 and Comparative Example 1 were let to sit at 40° C. in a relative humidity of 75% for 4 weeks. Then, the amount and activity of the epidermal growth factor were measured. The amount was measured using a reverse phase HPLC, and the activity was measured using ELISA. The obtained values are denoted as a percentage (%) with respect to initial values.
The results are shown in Table 2.
TABLE 2
Example Example Example Example Example Comparative
1 2 3 4 5 Example 1
Amount % 89 90 85 86 84 52
Activity % 90 92 87 85 84 60
As shown in Table 2, the liquid compositions according to the present invention show high stability with respect to thermal stress. Specifically, when the liquid composition is prepared using EDTA or L-histidine which is used as an antioxidant, the liquid composition shows much higher stability.
Test Example 2 Stability Test against Physical Stress
To identify physical stability of an epidermal growth factor with respect to an external physical stress, the liquid compositions prepared according to Examples 1-5 and Comparative Example 1 were stirred for 3 hours at 200 rpm and the generated agglutination was identified. The amount of the epidermal growth factor in each liquid composition was quantified after the generated agglutinate was removed (0.45 μm syringe filter, Millipore). The obtained values are denoted as a percentage (%) with respect to initial values. The results are shown in Table 3.
TABLE 3
Example Example Example Example Example Comparative
1 2 3 4 5 Example 1
Image Clean and Clean and Trace amount of Trace amount of Clean and Non-
Transparent Transparent agglutination agglutination Transparent transparent
forms (three to forms (one to
four particles) three particles)
Amount after 100.0 100.0 97.2 98.1 99.9 35.9
filtering %
As shown in Table 3, the liquid compositions according to the present invention show excellent stability with respect to a physical stress.
Examples 6-11
Liquid compositions were prepared according to the components and amounts shown in Table 4 in the same manner as in Examples 1-5. In Table 4, the amount of each component is represented by w/v %.
TABLE 4
Example Example Example Example Example Example
6 7 8 9 10 11
Active Epidermal 0.005 0.005 0.005 0.005 0.005 0.005
Component growth factor
Buffer Sodium 0.36 0.36 0.36 0.36 0.36 0.36
solution phosphate
monobasic
Isotonic Sodium chloride 0.87 0.87 0.87 0.87 0.87 0.87
agent
Preservative Methyl paraben 0.1 0.1 0.1 0.1 0.1 0.1
Stabilizer EDTA disodium 0.5 0.5 0.5 0.5 0.5 0.5
salt
Adhesive Poloxamer 407 10
polymer Hydroxypropyl 1
methyl cellulose
50 cps
Sodium 0.1
hyaluronate
Xanthan gum 0.2
Carbomer 940 0.5
Sodium 1.5
carboxymethyl
cellulose
Aqueous Refined water Appropriate Appropriate Appropriate Appropriate Appropriate Appropriate
medium
Viscosity (cps) 1500-2000
Test Example 3 Sensory Test
A sensory test was performed using the liquid compositions prepared according to Examples 6-11 and Comparative Example 1. Since patients suffering from serious stomatitis cannot eat food, a drug for treating stomatitis should not be simulative to oral mucous membrane and when the drug is applied to an oral carvity, a great amount of the drug should remain at a lesion. 35 patients suffering from stomatitis were grouped by 5 patients. Each liquid composition was applied to an inflammation site in oral cavity of each group. After 1 hour after the application, a feeling of use in consideration of a feeling of wearing and a stimulus of a tongue was questioned. The results are shown in Table 5. The values shown in Table 5 are means of the feelings of patients.
TABLE 5
Example Example Example Example Example Example Comparative
6 7 8 9 10 11 Example 1
Feeling of 7.5 10.0 9.5 9.5 9.0 10.0 7.0
Use
Feeling of 7.0 9.0 9.5 8.0 9.0 8.5 2.0
Wearing
Others bitter and None None None A bit None bitter and
acrid tastes bitter Taste acrid Tastes
Feeling of Use: from 10 (excellent, no stimulus) to 1 (bad, stimulus and painful)
Feeling of Wearing: from 10 (most of the drug used remains in the lesion) to 1 (most of the drug used flows to the esophagus)
Feeling of Use: from 10 (excellent, no stimulus) to 1 (bad, stimulus and painful)
Feeling of Wearing: from 10 (most of the drug used remains in the lesion) to 1 (most of the drug used flows to the esophagus)
As shown in Table 5, the liquid compositions according to the present invention show a good feeling of use. Specifically, when a liquid composition is prepared using a cellulose-based expicient, better feeling of use could be obtained.
Examples 12-16
Liquid compositions were prepared according to the components and amounts shown in Table 6 in the same manner as in Examples 1-5. In Table 6, the amount of each component is represented by w/v %.
TABLE 6
Example Example Example Example Example
12 13 14 15 16
Active Epidermal 0.005 0.005 0.005 0.005 0.005
Component growth factor
Buffer sodium 0.36 0.36 0.36 0.36 0.36
solution phosphate
monobasic
Isotonic Sodium chloride 0.87 0.87 0.87 0.87 0.87
agent
Preservative Methyl paraben 0.1 0.1 0.1 0.1 0.1
Stabilizer EDTA disodium 0.5
salt
L-histidine 1.0 1.0 1.0
Adhesive Poloxamer 407 6 9 9
polymer Hydroxypropyl 1
(thickener) methyl cellulose
50 cps
Sodium 1.5
carboxymethyl
cellulose
Aqueous Refined water Appropriate Appropriate Appropriate Appropriate Appropriate
medium amount amount amount amount amount
Viscosity (cps) 500-700 1200-1500
Test Example 4 Test for Room-temperature Stability
The liquid compositions prepared according to Examples 12-16 were let to sit at 25° C. in a relative humidity of 60% for 3 months. Then, the amount and activity of the epidermal growth factor were measured. The amount was measured using a reverse phase HPLC, and the activity was measured using ELISA. The obtained values are denoted as a percentage (%) with respect to initial values. The results are shown in Table 7.
TABLE 7
Example Example Example Example Example
12 13 14 15 16
Amount % 90.2 100.0 99.2 99.4 98.4
Activity % 89.3 99.1 98.3 100.5 99.1
As shown in Table 7, the liquid compositions according to the present invention show excellent stability for three months at room temperature.

Claims (11)

The invention claimed is:
1. A liquid pharmaceutical composition, comprising 0.0001 to 0.01 w/v % of an epidermal growth factor; 0.1 to 1.5 w/v % of an adhesive polymer selected from hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, sodium hyaluronic acid, or xanthan gum; and 0.5 to 1.0 w/v % of EDTA disodium salt,
wherein w/v % concentration is based on the total amount of the liquid pharmaceutical composition,
wherein the viscosity of the liquid pharmaceutical composition is in the range of 1500 to 2000 cps.
2. The liquid pharmaceutical composition of claim 1, wherein the stabilizer is 0.5 w/v % EDTA disodium salt.
3. A spray for treating stomatitis comprising the liquid pharmaceutical composition of claim 2.
4. The liquid pharmaceutical composition of claim 1, wherein the adhesive polymer is 1.0-1.5 w/v % of hydroxypropyl methyl cellulose.
5. A spray for treating stomatitis comprising the liquid pharmaceutical composition of claim 4.
6. The liquid pharmaceutical composition of claim 1, wherein the amount of the epidermal growth factor is 0.005 w/v % based on the total amount of the liquid composition.
7. A spray for treating stomatitis comprising the liquid pharmaceutical composition of claim 1.
8. The spray of claim 7, wherein the spray is a reconstitution spray comprising:
a solvent unit comprising an adhesive polymer; and
a primary component unit comprising an epidermal growth factor and a stabilizer,
wherein the solvent unit and the primary component unit are contained in different vessels from each other.
9. A method for treating stomatitis comprising
applying the liquid pharmaceutical composition of claim 1 to an oral inflammation site of a subject with stomatitis.
10. The method of claim 9, wherein the liquid pharmaceutical composition is in the form of a spray.
11. The liquid pharmaceutical composition of claim 1, comprising
0.005 w/v % epidermal growth factor, and
wherein the stabilizer is 0.5 w/v % EDTA disodium salt and
the adhesive polymer is 1.0-1.5 w/v % of hydroxypropyl methyl cellulose or sodium carboxymethyl cellulose.
US12/444,961 2006-10-09 2007-10-09 Stable liquid compositions for treating stomatitis comprising epidermal growth factor Active US9155697B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020060097734A KR100784134B1 (en) 2006-10-09 2006-10-09 Stable liquid compositions for treating mucositis comprising epidermal growth factor
KR10-2006-0097734 2006-10-09
PCT/KR2007/004911 WO2008044852A1 (en) 2006-10-09 2007-10-09 Stable liquid compositions for treating stomatitis comprising epidermal growth factor

Publications (2)

Publication Number Publication Date
US20100035809A1 US20100035809A1 (en) 2010-02-11
US9155697B2 true US9155697B2 (en) 2015-10-13

Family

ID=39140442

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/444,961 Active US9155697B2 (en) 2006-10-09 2007-10-09 Stable liquid compositions for treating stomatitis comprising epidermal growth factor

Country Status (8)

Country Link
US (1) US9155697B2 (en)
EP (1) EP2083797A4 (en)
JP (1) JP2010505942A (en)
KR (1) KR100784134B1 (en)
CN (1) CN101541305B (en)
MY (1) MY144321A (en)
TW (1) TWI370741B (en)
WO (1) WO2008044852A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
AU2012202981B2 (en) * 2009-09-30 2014-01-23 Cilag Gmbh International Adhesive Composition for Use in an Immunosensor
US8221994B2 (en) * 2009-09-30 2012-07-17 Cilag Gmbh International Adhesive composition for use in an immunosensor
KR101739414B1 (en) 2013-11-19 2017-05-24 아쿠아 메탈스 인크. Devices and method for smelterless recycling of lead acid batteries
WO2016183428A1 (en) 2015-05-13 2016-11-17 Aqua Metals Inc. Systems and methods for recovery of lead from lead acid batteries
EP3294931A4 (en) 2015-05-13 2018-12-26 Aqua Metals Inc. Electrodeposited lead composition, methods of production, and uses
PT3294929T (en) 2015-05-13 2021-07-15 Aqua Metals Inc Closed loop systems and methods for recycling lead acid batteries
US10316420B2 (en) 2015-12-02 2019-06-11 Aqua Metals Inc. Systems and methods for continuous alkaline lead acid battery recycling
CA3081094A1 (en) * 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
EP0267015A2 (en) 1986-11-05 1988-05-11 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
EP0312208A1 (en) 1987-09-18 1989-04-19 Ethicon, Inc. Gel formulations containing growth factors
WO1990012588A1 (en) 1989-04-14 1990-11-01 Berlex Laboratories, Inc. Treatment and prevention of oral mucositis with growth factors
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
KR960013439B1 (en) 1993-04-26 1996-10-05 주식회사 대웅제약 Stable epidermal growth factor composition
US5578310A (en) 1992-04-23 1996-11-26 Berlex Laboratories Inc. Topical bioadhesive ointment compositions and their use in wound healing
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
JPH10182481A (en) 1996-04-26 1998-07-07 Chugai Pharmaceut Co Ltd Erythropoietin solution preparation
WO2000056344A1 (en) 1999-03-24 2000-09-28 Seikagaku Corporation Artificial saliva
US6180601B1 (en) 1994-01-10 2001-01-30 Pharmacia Ab Low molecular weight hyaluronic acid with peptide or protein
WO2001041821A1 (en) * 1999-12-09 2001-06-14 Biosyntech Canada Inc. Mineral-polymer hybrid composition
WO2001062276A1 (en) 2000-02-21 2001-08-30 Daewoong Pharm. Co., Ltd. A stable composition comprising epidermal growth factor as an active ingredient
US6288113B1 (en) * 1997-08-27 2001-09-11 Welfide Corporation Angiogenesis promoters
CN1318415A (en) 2001-04-10 2001-10-24 王非 Buccal tablet of epidermal growth factor
WO2002017957A1 (en) 2000-09-01 2002-03-07 Chugai Seiyaku Kabushiki Kaisha Solution preparations stabilized over long time
JP2002255852A (en) 2001-03-01 2002-09-11 Toa Eiyo Ltd Spray preparation for stomatitis
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20030060486A1 (en) 2001-02-15 2003-03-27 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
WO2003095637A1 (en) 2002-01-29 2003-11-20 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
US20040063639A1 (en) 1997-12-22 2004-04-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO2004028557A1 (en) 2002-09-26 2004-04-08 Shionogi & Co., Ltd. Stabilized protein compositions
WO2004082590A2 (en) 2003-02-17 2004-09-30 Sun Pharmaceutical Industries Limited A low dose corticosteroid composition
KR20050055858A (en) 2003-12-09 2005-06-14 주식회사 엘지생활건강 The drug delivery system for the oral cavity
WO2006048501A1 (en) 2004-11-05 2006-05-11 Orion Corporation A transmucosal veterinary composition comprising detomidine
US20060128622A1 (en) * 2004-12-15 2006-06-15 Treuheit Michael J Therapeutic formulations of keratinocyte growth factor
WO2006071840A2 (en) 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP2006249085A (en) 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc Platform antibody composition
US20080226724A1 (en) * 2007-01-19 2008-09-18 Genentech, Inc. Prevention of hydrogel viscosity loss

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000056344A (en) * 1998-06-05 2000-02-25 Fuji Xerox Co Ltd Optical waveguide element and production of the same
JP5058404B2 (en) * 2000-07-03 2012-10-24 株式会社シリウス Slot machine
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267015A2 (en) 1986-11-05 1988-05-11 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JPS63152324A (en) 1986-11-05 1988-06-24 エチコン・インコーポレーテッド Epidermis growth factor-containing stabilized composition
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
EP0312208A1 (en) 1987-09-18 1989-04-19 Ethicon, Inc. Gel formulations containing growth factors
JPH05505170A (en) 1989-04-14 1993-08-05 シャーリング アクチェンゲゼルシャフト Treatment and prevention of oral mucositis with growth factors
WO1990012588A1 (en) 1989-04-14 1990-11-01 Berlex Laboratories, Inc. Treatment and prevention of oral mucositis with growth factors
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US5578310A (en) 1992-04-23 1996-11-26 Berlex Laboratories Inc. Topical bioadhesive ointment compositions and their use in wound healing
KR960013439B1 (en) 1993-04-26 1996-10-05 주식회사 대웅제약 Stable epidermal growth factor composition
US6180601B1 (en) 1994-01-10 2001-01-30 Pharmacia Ab Low molecular weight hyaluronic acid with peptide or protein
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JPH10182481A (en) 1996-04-26 1998-07-07 Chugai Pharmaceut Co Ltd Erythropoietin solution preparation
US6288113B1 (en) * 1997-08-27 2001-09-11 Welfide Corporation Angiogenesis promoters
US20040063639A1 (en) 1997-12-22 2004-04-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO2000056344A1 (en) 1999-03-24 2000-09-28 Seikagaku Corporation Artificial saliva
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2001041821A1 (en) * 1999-12-09 2001-06-14 Biosyntech Canada Inc. Mineral-polymer hybrid composition
WO2001062276A1 (en) 2000-02-21 2001-08-30 Daewoong Pharm. Co., Ltd. A stable composition comprising epidermal growth factor as an active ingredient
JP2003523399A (en) 2000-02-21 2003-08-05 ダエウン ファーマシューティカル カンパニー リミテッド Stable composition containing epidermal growth factor as active ingredient
WO2002017957A1 (en) 2000-09-01 2002-03-07 Chugai Seiyaku Kabushiki Kaisha Solution preparations stabilized over long time
US20030060486A1 (en) 2001-02-15 2003-03-27 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
JP2002255852A (en) 2001-03-01 2002-09-11 Toa Eiyo Ltd Spray preparation for stomatitis
CN1318415A (en) 2001-04-10 2001-10-24 王非 Buccal tablet of epidermal growth factor
WO2003095637A1 (en) 2002-01-29 2003-11-20 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
WO2004028557A1 (en) 2002-09-26 2004-04-08 Shionogi & Co., Ltd. Stabilized protein compositions
WO2004082590A2 (en) 2003-02-17 2004-09-30 Sun Pharmaceutical Industries Limited A low dose corticosteroid composition
JP2006517981A (en) 2003-02-17 2006-08-03 サン・ファーマシューティカル・インダストリーズ・リミテッド Low dose corticosteroid composition
KR20050055858A (en) 2003-12-09 2005-06-14 주식회사 엘지생활건강 The drug delivery system for the oral cavity
WO2006048501A1 (en) 2004-11-05 2006-05-11 Orion Corporation A transmucosal veterinary composition comprising detomidine
JP2008519012A (en) 2004-11-05 2008-06-05 オリオン コーポレーション Transmucosal animal composition containing detomidine
US20060128622A1 (en) * 2004-12-15 2006-06-15 Treuheit Michael J Therapeutic formulations of keratinocyte growth factor
WO2006071840A2 (en) 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP2006249085A (en) 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc Platform antibody composition
US20080226724A1 (en) * 2007-01-19 2008-09-18 Genentech, Inc. Prevention of hydrogel viscosity loss

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
EP Extended Search Report dated Oct. 1, 2012 for Application No. 07833222.8-2112.
Epstein, J. B. et al., "The Correlation Between Epidermal Growth Factor Levels in Saliva and the Severity of Oral Mucositis During Oropharyngeal Radiation Therapy", Am. Cancer Society, 2000, vol. 89 (11): 2258-2265.
Japanese Office Action issued Dec. 27, 2011 for Application No. JP 2009-532289.
Japanese Office Action issued Sep. 11, 2012 for Application No. JP 2009-532289.
Konturek et al., Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology vol. 94:1300-1307 (1988). *
Lee, K.K. et al., Recombinant Human Epidermal Growth Factor Accelerates Recovery of Mouse Small Intestinal Mucosa After Radiation Damage, Int J Radiat Oncol Biol Phys. 2008; 71(4):1230-1235.
Oshitani, et al. "Clinical Evaluation of Sodium Alginate on Oral Mucositis Associated with Radiotherapy," J. Jpn. Soc. Cancer Ther., 25(6): 1129-1137, (1990). (Translation of Abstract Only).
Sasaki et al. Keratinocyte growth factor and epidermal growth factor can reverse intestinal atrophy associated with elemental diets in mice. Experimal Physiology vol. 88/No. 2, pp. 261-267 (Mar. 2003). *
Tamura, et al., "Evaluation of Sodium Polyacrylate as the Dispersion Agent to Prepare Allopurinol Gargle," Div. of Pharm., Niigata Univ. Med. Hosp., 55(1), (1995). (Translation of Abstract Only).
Tanina, et al., "Stability and Therapeutical Efficacy of Allopurinol Gargle," Jpn. J. Hosp. Pharm., 18(5): 510-515, (1992). (Translation of Abstract Only).
Wu, H.G. et al., Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: A double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial, Cancer. 2009;115(16): 3699-3708. Doi: 10.1002/cncr.24414.

Also Published As

Publication number Publication date
KR100784134B1 (en) 2007-12-12
CN101541305B (en) 2012-04-11
TW200824719A (en) 2008-06-16
WO2008044852A1 (en) 2008-04-17
EP2083797A4 (en) 2012-10-31
TWI370741B (en) 2012-08-21
MY144321A (en) 2011-08-29
EP2083797A1 (en) 2009-08-05
CN101541305A (en) 2009-09-23
JP2010505942A (en) 2010-02-25
US20100035809A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
US9155697B2 (en) Stable liquid compositions for treating stomatitis comprising epidermal growth factor
KR101568681B1 (en) Stabilized pediatric suspension of carisbamate
EP1180368B1 (en) Freeze dried hgf preparations
JP4123309B2 (en) Pharmaceutical non-inorganic saline for intranasal administration
US11478456B2 (en) Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof
US20070203357A1 (en) Freeze-dried product of n-[o-(p-pivaloyloxy benzenesulfonylamino) benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof
WO2019038586A1 (en) Pharmaceutical composition of melatonin
BG65818B1 (en) Ciclesonide contained pharmaceutical composition for applicdtion to mucosa
US20080138383A1 (en) Compositions and methods for treating seizures
CN102481288B (en) Pharmaceutical composition of temozolomide comprising amino acid stabilizer and preparation method thereof
KR101840256B1 (en) A water-soluble eye drop composition for the treatment of dry eye syndrome containing rebamipide and its solubilization and stabilization method
JP6595717B2 (en) Composition comprising hydrophilized sulfasalazine and hyaluronic acid for the treatment of osteoarthritis and method for producing the same
JP6629877B2 (en) Pharmaceutical composition for nasal mucosal administration
CN107106659B (en) Parenteral glucagon formulations
JPS63166832A (en) Solution for nose
KR20060002795A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
WO2014059363A1 (en) Oral solution formulations of aripiprazole
JP3936324B2 (en) Oral antifungal agent
ES2738652T3 (en) Compositions of midazolam for oral administration in the treatment of seizures to obtain rapid onset of action
JP7273257B1 (en) Pharmaceutical composition
JPS63303931A (en) Drug preparation for transnasal administration having growth hormone releasing activity
WO2023100836A1 (en) Pharmaceutical composition
JPS63316737A (en) Medicine composition for dermal administration
US20050136116A1 (en) Stabilized prednisolone sodium phosphate solutions
GB2619970A (en) An orodispersible pharmaceutical composition of baclofen and its process of preparation

Legal Events

Date Code Title Description
AS Assignment

Owner name: DAEWOONG CO., LTD.,KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, SUN-HEE;LEE, SANG-KIL;YOON, CHAE-HA;AND OTHERS;SIGNING DATES FROM 20090315 TO 20090408;REEL/FRAME:022810/0511

Owner name: DAEWOONG CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, SUN-HEE;LEE, SANG-KIL;YOON, CHAE-HA;AND OTHERS;SIGNING DATES FROM 20090315 TO 20090408;REEL/FRAME:022810/0511

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8